Dona, 200 mg/ml 2 ml 6 pcs

DONA – has anti-inflammatory and analgesic effect, fills the endogenous deficit of glucosamine, stimulates the synthesis of proteoglycans and hyaluronic acid synovial fluid; increases the permeability of the joint capsule, restores enzymatic processes in the cells of synovial membrane and articular cartilage.

It promotes sulfur fixation in the synthesis of chondroitinous acid, facilitates normal calcium deposition in bone tissue, inhibits the development of degenerative processes in joints, restores their function, reducing joint pain.

Pharmacokinetics

When administered intramuscularly the bioavailability is 95%, rapidly distributed to tissues, half-life is about 60 hours, excreted mainly by the kidneys.

Indications

Primary and secondary osteoarthritis, osteochondrosis, spondyloarthrosis.

Pharmacological effect

When administered intramuscularly, bioavailability is 95%, rapidly distributed in tissues, half-life about 60 hours, excreted mainly by the kidneys.

Special instructions

When using the drug in patients with impaired glucose tolerance, with severe liver and kidney failure, medical supervision is required.

Active ingredient

Glucosamine

Composition

Solution A: each ampoule (2 ml) contains:
active ingredient: crystalline glucosamine sulfate 502.5 mg (contains 400 mg
glucosamine sulfate and 102.5 mg sodium chloride);
excipients: lidocaine hydrochloride 10.0 mg, water for injection up to 2 ml.

Solution B: ampoule volume (1 ml) contains:
excipients: diethanolamine – 24.0 mg, water for injection up to 1 ml.

Contraindications

Individual hypersensitivity to glucosamine, lidocaine hydrochloride and other components of the drug. Due to the presence of lidocaine in the product, it is contraindicated in patients with cardiac conduction disorders and acute heart failure, a history of epileptiform seizures, severe liver and kidney dysfunction; during pregnancy and lactation, as well as in children under 12 years of age.

Side Effects

The drug is well tolerated. In some cases, possible: flatulence, diarrhea, constipation, allergic reactions – urticaria, itching. Due to the content of lidocaine in the drug, the following are possible: nausea, vomiting, drowsiness, diplopia, headache, dizziness, numbness of the tongue and oral mucosa, tremor, euphoria, disorientation, cardiac conduction disturbances.

Interaction

Compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids.
Caution should be exercised when prescribing injections of the drug in combination with beta-blockers, digitoxin, ajmaline, amiodarone, verapamil, quinidine, procainamide, hexenal or sodium thiopental, MAO inhibitors, polymyxin-B, hypnotics or sedatives, cimetidine.

Overdose

No cases of overdose have been reported.

Clinical pharmacology

DONA – has an anti-inflammatory and analgesic effect, replenishes endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans and hyaluronic acid in synovial fluid; increases the permeability of the joint capsule, restores enzymatic processes in the cells of the synovial membrane and articular cartilage. Promotes fixation of sulfur in the process of chondroitinsulfuric acid synthesis, facilitates normal calcium deposition in bone tissue, inhibits the development of degenerative processes in joints, restores their function, reducing joint pain.

Short product description

Pharmacotherapeutic group: tissue repair stimulator.

Storage conditions

At a temperature not exceeding 25° C.
Keep out of the reach of children.

Shelf life

2 years.
Do not use the drug after the expiration date indicated on the package.

Manufacturer

Biologici Italia Laboratories S.r.L., Italy